First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours
Isabella Silins, Anders Sundin, Mark Lubberink, Lleah O'Sullivan, Mark Gurnell, Franklin Aigbirhio, Morris Brown, Anders Wall, Tobias Åkerström, Sara Roslin, Per Hellman, Gunnar Antoni, Isabella Silins, Anders Sundin, Mark Lubberink, Lleah O'Sullivan, Mark Gurnell, Franklin Aigbirhio, Morris Brown, Anders Wall, Tobias Åkerström, Sara Roslin, Per Hellman, Gunnar Antoni
Abstract
Purpose: [11C]Metomidate positron emission tomography (PET) is currently used for staging of adrenocortical carcinoma and for lateralization in primary aldosteronism (PA). Due to the short half-life of carbon-11 and a high non-specific liver uptake of [11C]metomidate there is a need for improved adrenal imaging methods. In a previous pre-clinical study para-chloro-2-[18F]fluoroethyletomidate has been proven to be a specific adrenal tracer. The objective is to perform a first evaluation of para-chloro-2-[18F]fluoroethyletomidate positron emission computed tomography ([18F]CETO-PET/CT) in patients with adrenal tumours and healthy volunteers.
Methods: Fifteen patients underwent [18F]CETO-PET/CT. Five healthy volunteers were recruited for test-retest analysis and three out of the five underwent additional [15O]water PET/CT to measure adrenal blood flow. Arterial blood sampling and tracer metabolite analysis was performed. The kinetics of [18F]CETO were assessed and simplified quantitative methods were validated by comparison to outcome measures of tracer kinetic analysis.
Results: Uptake of [18F]CETO was low in the liver and high in adrenals. Initial metabolization was rapid, followed by a plateau. The kinetics of [18F]CETO in healthy adrenals and all adrenal pathologies, except for adrenocortical carcinoma, were best described by an irreversible single-tissue compartment model. Standardized uptake values (SUV) correlated well with the uptake rate constant K1. Both K1 and SUV were highly correlated to adrenal blood flow in healthy controls. Repeatability coefficients of K1, SUV65-70, and SUV120 were 25, 22, and 17%.
Conclusions: High adrenal uptake combined with a low unspecific liver uptake suggests that 18F]CETO is a suitable tracer for adrenal imaging. Adrenal SUV, based on a whole-body scan at 1 h p.i., correlated well with the net uptake rate Ki.
Trial registration: ClinicalTrials.gov , NCT05361083 Retrospectively registered 29 April 2022. at, https://ichgcp.net/clinical-trials-registry/NCT05361083.
Keywords: Adrenal tracer; Positron emission tomography; [18F]CETO.
Conflict of interest statement
The authors declare no competing interests.
© 2022. The Author(s).
Figures
References
- Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Åkerström G, et al. In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11- metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med. 1998;39:982–989.
- Chen Cardenas SM, Santhanam P. (11)C-metomidate PET in the diagnosis of adrenal masses and primary aldosteronism: a review of the literature. Endocrine. 2020;70:479–487. doi: 10.1007/s12020-020-02474-3.
- Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab. 2012;97:100–109. doi: 10.1210/jc.2011-1537.
- Ouyang J, Hardy R, Brown M, Helliwell T, Gurnell M, Cuthbertson DJ. (11)C-metomidate PET-CT scanning can identify aldosterone-producing adenomas after unsuccessful lateralisation with CT/MRI and adrenal venous sampling. J Hum Hypertens. 2017;31:483–484. doi: 10.1038/jhh.2017.9.
- Khan TS, Sundin A, Juhlin C, Langstrom B, Bergstrom M, Eriksson B. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging. 2003;30:403–410. doi: 10.1007/s00259-002-1025-9.
- Wadsak W, Mitterhauser M, Rendl G, Schuetz M, Mien LK, Ettlinger DE, et al. [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging. 2006;33:669-72.
- Bongarzone S, Basagni F, Sementa T, Singh N, Gakpetor C, Faugeras V, et al. Development of [18F]FAMTO: a novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands. Int J Nucl Med Biol. 2018;68-69:14-21.
- Abe T, Naruse M, Young WF, Jr, Kobashi N, Doi Y, Izawa A, et al. A novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2016;101:1008–1015. doi: 10.1210/jc.2015-3431.
- Sander K, Gendron T, Cybulska KA, Sirindil F, Zhou J, Kalber TL, et al. Development of [(18)F]AldoView as the first highly selective aldosterone synthase pet tracer for imaging of primary hyperaldosteronism. J Med Chem. 2021;64:9321–9329. doi: 10.1021/acs.jmedchem.1c00539.
- Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology. 2002;222:629–633. doi: 10.1148/radiol.2223010766.
- Rossi GP, Chiesura-Corona M, Tregnaghi A, Zanin L, Perale R, Soattin S, et al. Imaging of aldosterone-secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism. J Hum Hypertens. 1993;7:357–363.
- Williams TA, Reincke M. MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol. 2018;179:R19–R29. doi: 10.1530/EJE-17-0990.
- Jakobsson H, Farmaki K, Sakinis A, Ehn O, Johannsson G, Ragnarsson O. Adrenal venous sampling: the learning curve of a single interventionalist with 282 consecutive procedures. Diagn Interv Radiol. 2018;24:89–93.
- Erlandsson M, Karimi F, Lindhe O, Langstrom B. (18)F-labelled metomidate analogues as adrenocortical imaging agents. Int J Nucl Med Biol. 2009;36:435-45.
- Silins I, Sundin A, Nordeman P, Jahan M, Estrada S, Monazzam A, et al. Para-chloro-2-[18F]fluoroethyl-etomidate: a promising new PET radiotracer for adrenocortical imaging. Int J Med Sci. 2021;18:2187–2196. doi: 10.7150/ijms.51206.
- Miller PW, Long NJ, Vilar R, Gee AD. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew Chem Int Ed Engl. 2008;47:8998–9033. doi: 10.1002/anie.200800222.
- Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175:G1–G34. doi: 10.1530/EJE-16-0467.
- Boellaard R, van Lingen A, van Balen SC, Hoving BG, Lammertsma AA. Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med. 2001;28:81–89. doi: 10.1007/s002590000405.
- Akaike H. Statistical predictor identification. Ann Inst Stat Math. 1970;22:203–217. doi: 10.1007/BF02506337.
- Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1–7. doi: 10.1038/jcbfm.1983.1.
- Gurnell M. CETO first in human trial (CETO). Identifier: NCT04529018. 2020, August-. .
- Gurnell M. MATCH trial extension. Identifier: NCT02945904. 2016, October-. .
- Jung B, Nougaret S, Chanques G, Mercier G, Cisse M, Aufort S, et al. The absence of adrenal gland enlargement during septic shock predicts mortality: a computed tomography study of 239 patients. Anesthesiology. 2011;115:334–343. doi: 10.1097/ALN.0b013e318225cfd7.
Source: PubMed